Navigation Links
Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement
Date:12/6/2011

WAYNE, N.J. and URBANA, Ill., Dec. 6, 2011 /PRNewswire/ -- Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron® (interferon beta-1b) to reduce the frequency of clinical exacerbations.  The agreement is the first of this type for Bayer HealthCare in the U.S. and is defined by relapses requiring hospitalizations for Betaseron patients covered by Health Alliance. 

"Bayer continually identifies and implements innovative means of supporting our patients," said Alex Santini, Vice President, Managed Markets, Bayer HealthCare.  "This agreement reinforces our commitment to people taking Betaseron and demonstrates our belief that when patients are adherent to their treatment plan, there may be a greater chance for positive outcomes by reducing clinical exacerbations."

Both companies are committed to providing support to people taking Betaseron.  Bayer's patient support program, BETAPLUS®, is designed to help patients get started successfully on Betaseron and remain on their treatment plan.  It provides round-the-clock nurse assistance and access specialists who answer insurance-related questions, among other services.  Health Alliance emphasizes wellness, education and prevention and has assembled networks of the best healthcare professionals.  The National Committee for Quality Assurance (NCQA) has awarded Health Alliance its highest accreditation for its HMO, POS and Medicare HMO products since 1997.

"Today's healthcare environment calls for new ways to improve patient outcomes and reduce costs associated with disease management," said Robert Parker, MD, Chief Medical Officer at Health Alliance.  "This agreement represents the best efforts of Bayer and Health Alliance to address the needs of patients while taking into account economic realities."

INDICATION
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... International Trade Commission (ITC) issued its final decision in the ... notice issued on December 23, the ITC ruled in favor ... was invalid. BMC President, James Xu ... with the ITC,s decision in this case. This victory for ... very beginning on the key patents in the case. ResMed ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... 2011 Reportlinker.com announces that a ... in its catalogue: ... - Pipeline Assessment and Market Forecasts ... http://www.reportlinker.com/p0617091/Post-Menopausal-Hormone-Replacement-Therapy-HRT---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy Post-Menopausal ...
... CHENGDU, China, Sept. 19, 2011, /PRNewswire-Asia-FirstCall/ -- ... or the "Company"), a pharmaceutical company that ... Chinese medicine, branded generics and active pharmaceutical ... for its operating subsidiary, Chengdu Tianyin Pharmaceutical ...
Cached Medicine Technology:Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 3Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 4Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 5Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 6Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 7Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 8Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 9TPI Provides Updates on the Renewal Application for High Tech Enterprise Status 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... type 2 diabetes is dramatically increasing throughout the world. ... and it most often precedes the onset of hyperglycemia ... thiazolidinediones (TZD), the agonists of the peroxisome proliferators-activated receptor ... in the liver, adipose tissue, and skeletal muscle, thus ...
... Gordon HealthDay Reporter , MONDAY, March 14 (HealthDay ... medications for type 2 diabetes, an older drug -- metformin ... new analysis of research on diabetes medications. The ... that all of them lower blood sugar levels by a ...
... 15 (HealthDay News) -- Having a bad, short-term or poorly ... having no job, according to a new study. Researchers ... in Australia and were not surprised to find that those ... with jobs. However, the study authors also found that ...
... A nursing home industry is booming in China ... elderly population forces a nationwide shift from traditional family ... Brown University gerontologists. The study, led by Zhanlian ... in the Journal of the American Geriatrics Society ...
... If all eligible patients filled their prescriptions through a $4 ... $6 billion, according to a University of Pittsburgh Graduate School ... issue of Archives of Internal Medicine , the study ... a broad use of discounted generic medication programs that are ...
... -- The benefits of bariatric (weight loss) surgery may ... to a new scientific statement from the American Heart ... absorption of food as it passes through the ... person,s caloric intake. The statement-writing committee reviewed ...
Cached Medicine News:Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 3Health News:Bad Job May Be Worse for Mental Health Than No Job at All 2Health News:Nursing home boom in China has little government involvement 2Health News:Nursing home boom in China has little government involvement 3Health News:Use of $4 generic drug programs could save society billions of dollars, study shows 2Health News:Benefits of Weight-Loss Surgery May Outweigh Risks for Some, Experts Say 2
Thermal Seal, Clear, Bulk...
Acetate Plate Sealers 100/Box...
... seals provide an adhesive-based sealing option for ... adhesive layer ensures secure sample storage or ... sealing during thermal cycling when supplemental pressure ... perforated end-tabs can be removed when using ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Medicine Products: